Stem cell defects after cytoreductive therapy in man

Area of Science:

• Hematology
• Oncology
• Stem Cell Biology

Background:

• Hematotoxicity is a major dose-limiting side effect of cytoreductive therapy.
• Studying stem cell defects in humans post-therapy faces methodological challenges, including limitations in bone marrow sampling.
• Ethical considerations restrict serial bone marrow specimen collection.

Purpose of the Study:

• To investigate the reaction of human hematopoietic stem cells and precursor pools to cytostatic chemotherapy regimens.
• To assess the utility of peripheral blood colony-forming units (CFU) in monitoring long-term hematopoietic damage.
• To develop methods for quantifying bone marrow stem cell defects.

Main Methods:

• Studied colony-forming unit granulocyte-macrophage (CFU-GM), CFU-erythroid (CFU-E), and burst-forming unit-erythroid (BFU-E) in bone marrow (BM) and peripheral blood (PB).
• Utilized BM spicule morphometry and aspirate cellularity to develop a quantification index for BM data.
• Monitored patients undergoing various adjuvant and palliative chemotherapy regimens for human cancer.

Main Results:

• Acute reactions of bone marrow stem cells and precursor pools mirrored findings in animal models.
• Peripheral blood CFU-GM proved important for detecting long-term hematopoietic derangements in humans.
• Observed stem cell defects in BM and PB not reflected in peripheral blood counts, particularly after nitrosourea treatment.
• Detected prolonged stem cell derangements up to five years post-chemotherapy, especially after adjuvant therapy for breast cancer.

Conclusions:

• Peripheral blood CFU-GM is a valuable indicator of long-term hematopoietic stem cell damage in cancer patients.
• Developed a novel index for quantifying bone marrow stem cell defects, aiding in understanding chemotherapy's impact.
• Stem cell defects can persist long after treatment, even when peripheral blood counts normalize.
• Recommends monitoring stem cell data for new chemotherapeutic regimens to mitigate early and late hematopoiesis side effects.